🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Malignant Melanoma of Skin

An Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid Tumors NCT07371663Phase 1, Phase 23 sites📍 Beijing📍 Zhengzhou📍 Hangzhou Beijing Tide Pharmaceutical Co., Ltd · Tests: TCC1727 tablet 90mg, TCC1727 tablet 120mg, TCC1727 tablet 160mg, benmelstobart Injection Comparing Tunlametinib Capsules and Combination Chemotherapy in Advanced NRAS-mutant Melanoma NCT06008106Phase 31 site📍 Beijing Shanghai Kechow Pharma, Inc. · Tests: tunlametinib, paclitaxel +carboplatin, or temozolomide +cisplatin, or dacarbazine +cisplatin Evaluation of Hypoxia in Primary Melanoma NCT06831071n/a1 site📍 Pittsburgh Yana Najjar · Tests: Pimonidazole Naltrexone and Propranolol Combined With Immunotherapy NCT05968690Phase 11 site📍 New Brunswick Sarah Weiss · Tests: Propranolol, Naltrexone A Clinical Study of LM103 Injection in the Treatment of Advanced Solid Tumors NCT05366478Phase 11 site📍 Tianjin Suzhou BlueHorse Therapeutics Co., Ltd. · Tests: Autologous tumor infiltrating lymphocytes (TILs) Timing of Immunotherapy in Melanoma NCT07696715NA5 sites📍 Amsterdam📍 Amsterdam📍 Leiden Radboud University Medical Center · Tests: Timing of first administration (early morning), Timing of immunotherapy (afternoon) A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab NCT02621021Phase 21 site📍 Bethesda National Cancer Institute (NCI) · Tests: young TIL, Pembrolizumab, Aldesleukin, Fludarabine, Cyclophosphamide A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02) NCT06330064Phase 1, Phase 2120 sites📍 Los Angeles📍 Los Angeles📍 Whittier Daiichi Sankyo · Tests: Ifinatamab deruxtecan Tebentafusp-tebn With LDT in Metastatic UM NCT06626516Phase 1, Phase 21 site📍 Philadelphia Thomas Jefferson University · Tests: Tebentafusp-Tebn, GM-CSF (Sargramostim), BCNU Study of GV20-0251 in Participants With Solid Tumor Malignancies NCT07070518Phase 1, Phase 23 sites📍 Beijing📍 Beijing📍 Shanghai GV20 Therapeutics · Tests: GV20-0251 A Study of Biological, Genetic, and Constitutional Factors and Non-invasive Monitoring to Assess Personal Cancer Risks NCT07469709n/a1 site📍 Candiolo Fondazione del Piemonte per l'Oncologia Efficacy And Safety Of Anti-PD-1/PD-L1 Antibodies In Combination With Bevacizumab And Metronomic Cyclophosphamide In Patients With Non-Small Cell Lung Cancer And Cutaneous Melanoma Previously Treated With Immune Checkpoint Blockade NCT07130032Phase 21 site📍 Saint Petersburg EuroCityClinic LLC · Tests: reICB regimen (NSCLC), reICB regimen (melanoma) Photodynamic Therapy Associated With Sonodynamic Therapy for the Treatment of Nodular Basal Cell Carcinoma NCT07381972Phase 31 site📍 Jaú University of Sao Paulo · Tests: Control Arm (Conventional Therapy), Experimental arm Real-world Evaluation of the Implementation of LC-OCT in Daily Clinical Practice NCT07501780n/a1 site📍 Maastricht Maastricht University Medical Center A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors NCT04895709Phase 1, Phase 247 sites📍 Clovis📍 Los Angeles📍 Newport Beach Bristol-Myers Squibb · Tests: BMS-986340, BMS-936558-01, Docetaxel, Pumitamig DETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition NCT05770102Phase 2, Phase 327 sites📍 Belfast📍 Birmingham📍 Birmingham Cancer Research UK · Tests: Atezolizumab A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy NCT06362369Phase 1, Phase 25 sites📍 Aurora📍 Lake Mary📍 Lebanon 7 Hills Pharma, LLC · Tests: Alintegimod, Ipilimumab, Nivolumab Bright Light Therapy in Patients With Melanoma or Non-small Cell Lung Cancer (NSCLC) Who Are Receiving First-Line Immune Checkpoint Blockade NCT07661966NA1 site📍 New York Weill Medical College of Cornell University · Tests: Bright Light Therapy The Study Aims to Measure the Metabolome in Melanoma Patients Using NMR Spectroscopy and Gas Chromatography and to Analyse Differences Depending on the Course of the Disease. NCT06765850n/a1 site📍 Dresden Technische Universität Dresden Investigating the Combination of Bexmarilimab and Nivolumab in Solid Tumours, Melanoma and NSCLC NCT07718243Phase 1, Phase 22 sites📍 Manchester📍 Sutton Institute of Cancer Research, United Kingdom · Tests: Bexmarilimab 1mg/kg and nivolumab 1mg/kg, Bexmarilimab 3mg/kg and nivolumab 1mg/kg, Recommended Phase II Dose START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer NCT05492682Phase 17 sites📍 Frankfurt📍 Heidelberg📍 Tübingen Valo Therapeutics Oy · Tests: PeptiCRAd-1, Cyclophosphamide, Pembrolizumab Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM) NCT05549297Phase 382 sites📍 Phoenix📍 Jacksonville📍 Orlando Immunocore Ltd · Tests: Tebentafusp, Tebentafusp with Pembrolizumab, Investigators Choice Mirdametinib in Patients With Advanced NF1-mutant Melanoma NCT07237100Phase 21 site📍 San Francisco Kevin Kim, MD · Tests: Mirdametinib AI-Driven Early Detection of Skin Cancer NCT07144306n/a1 site📍 London Nuvana Healthcare LTD · Tests: Smartphone-based AI skin lesion analysis (NuvanaDx platform). An Open-label, Phase I Clinical Trial of Super1 TCR-T in NY-ESO-1-positive Patients With Advanced Solid Tumors NCT06942143Phase 11 site📍 Guangzhou Guangzhou FineImmune Biotechnology Co., LTD. · Tests: Super1 TCR-T Binimetinib and Imatinib for Unresectable Stage III-IV KIT-Mutant Melanoma NCT04598009Phase 22 sites📍 La Jolla📍 San Francisco University of California, San Francisco · Tests: Binimetinib, Imatinib Intralesional Influenza Vaccine for the Treatment of Stage I-IV Melanoma NCT04697576Phase 11 site📍 Columbus Carlo Contreras · Tests: Ipilimumab, Nivolumab, Pembrolizumab, Quadrivalent Inactivated Influenza Vaccine, Resection A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors NCT07115043Phase 1, Phase 213 sites📍 Grand Rapids📍 St Louis📍 Pittsburgh AstraZeneca · Tests: AZD6750, rilvegostomig Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases NCT03093909Phase 11 site📍 Houston M.D. Anderson Cancer Center · Tests: Gemcitabine Feasibility Study on the Effect of a Methionine-Reduced Diet on Serum Levels in Pts w/ Solid Tumors NCT07628634EARLY Phase 11 site📍 Orange University of California, Irvine · Tests: Methionine-Reduced Diet
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy